This Week in Science

A team from Brandeis University reports in Science this week on the discovery of a handful of ancient genetic mutations that are responsible for the activity of the cancer drug Gleevec against tumors expressing one type of oncogene, but not a related one. Gleevec works by blocking the activity of Abl tyrosine kinase, but is ineffective against closely homologous tyrosine kinases such as Src.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.